We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.
Harvard Medical School’s Richard Sherwood digs into the potential and pitfalls of gene editing technology.
How DNA origami nanostructures could find their way into the treatment of acute kidney injury.
Two chemical components; opposite effects. How medical marijuana impacts glaucoma for better – and for worse.
We sat down with David Eidelberg shortly after the publication of his group’s most recent paper in Science Translational Medicine.
Sitting Down With… Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland.
A new method for discovering antibiotics makes use of an unusual source of complex microbial communities: bear saliva.
Could activated T cells play a major role in driving neurodegeneration in glaucoma?
A promising candidate is on the verge of entering clinical development… What happens when you see an opportunity to make it even better?
For better diagnosis and monitoring of Alzheimer’s disease, as well as drug R&D, we need to move toward widespread use of MRI biomarker imaging.
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.